News

Public · Published

Guggenheim maintains Insmed at Buy, lowers price target to $201 from $205

Guggenheim kept its Buy rating on Insmed but cut its price target to $201 from $205, a 2.0% decrease. The revised target implies 78.5% upside from Insmed's October 30 closing price of $112.58. Recent analyst targets listed in the article range from $213 to $220.

Published:

Updated:

What happened

Guggenheim kept its Buy rating on Insmed but cut its price target to $201 from $205, a 2.0% decrease. The revised target implies 78.5% upside from Insmed’s October 30 closing price of $112.58. Recent analyst targets listed in the article range from $213 to $220.

Confirmed

Global impact / market context

The lower target signals a modestly less optimistic valuation from Guggenheim, even though its Buy rating is unchanged. Analyst targets can shape investor expectations and positioning, but they are opinions rather than company results and do not establish that Insmed’s revenue, costs, or cash position have changed.

Analyst inference

Recent analyst views in the article are mixed: Morgan Stanley maintained an Overweight rating with a $213 target, Wolfe Research downgraded Insmed to Peer Perform without a target, and another firm reiterated Buy at $220. This range of opinions may shape investor positioning, but does not establish future performance.

Analyst inference

What to watch

  1. Watch for future Insmed analyst updates: changes to ratings or targets could shift investor expectations, though the article gives no explanation for Guggenheim’s reduction. Analyst inference
  2. Compare later company disclosures with the assumptions behind analyst targets, especially any reported changes in revenue, costs, or cash available; none are described here. Analyst inference
  3. The article reports Guggenheim’s $201 target and unchanged Buy rating, but does not state whether the firm expects to revise either again. Confirmed

Evidence

  • Original source link unavailable